Kancera AB (publ) Stock Nasdaq Stockholm
Equities
SE0015658570
Biotechnology & Medical Research
Sales 2023 | 1.03M 95.7K 131K | Sales 2024 * | - | Capitalization | 184M 17.05M 23.34M |
---|---|---|---|---|---|
Net income 2023 | -64M -5.92M -8.1M | Net income 2024 * | -81M -7.49M -10.25M | EV / Sales 2023 | 358 x |
Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | - |
P/E ratio 2023 |
-9.28
x | P/E ratio 2024 * |
-2.17
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 37.38% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 22-02-28 |
Director of Finance/CFO | 75 | - | |
Martin Norin
COO | Chief Operating Officer | 65 | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 10-05-04 | |
Director/Board Member | 66 | 15-12-31 | |
Håkan Mellstedt
FOU | Founder | 82 | 10-04-27 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |